We’ve been there from the start, working tirelessly alongside you to help define the practice of electrophysiology. We’ve been expanding indications and conducting pivotal research for nearly 20 years, resulting in increased access to the lifesaving and life-enhancing benefits of ICD and CRT therapies.
ESC 2011 - The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy - Results from the SMART-AV Trial >>
Non-responders continue to be a challenge for CRT therapy despite optimized device programming. Recent studies suggest that a purely anatomic approach to lead position may be of limited value. This ESC 2011 late breaking study and European Heart Journal manuscript looks at the potential use of the QLV interval to guide lead placement or repositioning to optimize CRT response.
Boston Scientific continues to demonstrate its commitment to the advancement of heart failure treatment >>
MADIT-CRT provides definitive insight into a frequently asked and critically important question about the potential of resynchronization defibrillator therapy to intervene earlier in the natural history of heart failure progression. Early CRT intervention enables you to reduce death and heart failure events in your patents' earliest phase of heart failure -- regardless of the presence of symptoms.
Boston Scientific welcomes publication of gender data showing women received greater benefit from CRT-Ds than men. This article is located in the Heart Rhythm Disorders section.
The Investigator-Sponsored Research (ISR) Program facilitates the support of researchers by funding studies that are of interest to Boston Scientific and the medical community.
Learn more about the ISR Program
The ALTITUDE Survival Study, which analyzed long term patient outcomes and the influence of remote device follow-up on over 194,000 patients, was recently published in the Dec 7th issue of Circulation.
Click here to access a copy of the manuscript